Association of Casp3 MicroRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma
Overview
Oncology
Authors
Affiliations
Objective: In the present study, we investigated the relationship between the single-nucleotide polymorphism (SNP) of caspase-3 rs1049216 (C > T), a miRNA target site, and the risk and progression of cervical cancer.
Materials And Methods: Using polymerase chain reaction-restriction fragment length polymorphism, we evaluated the genotype and distribution of caspase-3 rs1049216 in 515 patients with cervical squamous cell cancer and 415 controls. In additional experiments, we transfected luciferase reporter plasmids carrying T or C allele and/or miRNA mimics into the human cervical cell lines (HeLa and C-33A) to analyze its roles in the regulation of caspase-3 expression. By immunohistochemistry, the protein level of caspase-3 expression was examined in tumor tissues from 515 patients with cervical squamous cell cancer.
Results: We found that the TT genotype of caspase-3 rs1049216 conferred a significantly decreased risk of cervical cancer (adjusted odds ratio, 0.35; 95% confidence interval, 0.154-0.581) and may be associated with the progression of this cancer. Although the expression of caspase-3 in the TT genotype was higher than that in CC/CT genotype in peripheral blood mononuclear cells and tumor tissues. Additional luciferase analysis showed that the rs1049216 variant T allele was associated with significantly higher luciferase activity, compared with the C allele in the transfected cells, and when cotransfected with miRNAs, miRNA-181a could downregulate the luciferase activity in the cells that transfected the construct containing C allele, compared with T allele, which had not happened in the presence of other miRNAs selected.
Conclusions: These data indicate that through upregulating the expression of caspase-3, the TT genotype of caspase-3 rs1049216 can be associated with not only the risk of cervical cancer but also the progression of this cancer.
Wang R, Zhang Z, Li D, Wu N, Peng Z J Med Biochem. 2023; 42(3):412-419.
PMID: 37814615 PMC: 10560501. DOI: 10.5937/jomb0-37763.
Li R, Wu J, Guo M, Sha L, Xia S, Xu L Pharmgenomics Pers Med. 2021; 14:705-712.
PMID: 34163215 PMC: 8216076. DOI: 10.2147/PGPM.S310504.
Guo L, Liang Y Exp Ther Med. 2017; 14(6):6007-6011.
PMID: 29285150 PMC: 5740686. DOI: 10.3892/etm.2017.5299.